Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q99643

UPID:
C560_HUMAN

ALTERNATIVE NAMES:
Integral membrane protein CII-3; QPs-1; Succinate dehydrogenase complex subunit C; Succinate-ubiquinone oxidoreductase cytochrome B large subunit

ALTERNATIVE UPACC:
Q99643; O75609; Q3C259; Q3C2D8; Q3C2H4; Q5VTH3

BACKGROUND:
Succinate dehydrogenase cytochrome b560 subunit, mitochondrial, also referred to as Succinate-ubiquinone oxidoreductase cytochrome B large subunit, Integral membrane protein CII-3, QPs-1, and Succinate dehydrogenase complex subunit C, is integral to complex II of the mitochondrial electron transport chain. This protein is essential for the conversion of succinate to ubiquinone, a key step in metabolic processes.

THERAPEUTIC SIGNIFICANCE:
The association of this protein with diseases such as Paragangliomas 3 and Paraganglioma and gastric stromal sarcoma highlights its potential as a target for therapeutic intervention. The exploration of its function and the development of drugs targeting its activity could offer new avenues for treating these complex diseases, making it a significant focus for drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.